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Laparoscopic colectomy is now widely applied to cases of malignancy, supported by early data from several large
randomized controlled trials. Long-term follow-up is now available from those trials, supporting equivalency of
cancer-free and overall survival for open and laparoscopic resections. This promising data has inspired further
exploration of other applications of laparoscopic techniques, including use of single incision laparoscopy. This
article reviews recent reports of long-term data for colorectal cancer resection from four randomized, prospective
international trials.
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Colorectal cancer remains the second leading cause of
cancer-related death in Western countries [1]. Despite
advancements of medical treatments, surgical excision
remains the only definitive therapy for colorectal cancer.
The first reported laparoscopic sigmoid resection in
1991 inspired the application of laparoscopy to a range
of colorectal disease, including cancer [2]. The reported
short-term benefits of laparoscopy include less post-
operative pain, faster return of bowel function, shorter
hospitalization, and overall improved quality of life [3].
In spite of these benefits, reports of port-site tumor re-
currence and the ability to perform adequate lymphade-
nectomy raised concerns for the safety and adequacy of
laparoscopic oncologic resections [4]. These concerns
prompted the design of several studies, including four
large randomized controlled trials (RCT) that are now
generating 3 and 5-year follow-up data. Short-term and
3-year outcomes from three studies supported that over-
all and cancer-free survivals with laparoscopy were not
significantly different from conventional open resection.
The objective of this review is to provide an update on
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reproduction in any medium, provided the orof laparoscopy continues to evolve with newer techni-
ques and instruments, providing both better outcomes
and a wider range of application in the field of colorectal
surgery. This article also aims to review the available
outcomes regarding laparoscopic rectal cancer resection,
as well as utilization of the single-site incision laparo-
scopic (SIL) technique.Colon cancer
COST: clinical outcomes of surgical therapy study group
COST analyzed 863 patients among 48 centers in the
United States and Canada. With insufficient data sug-
gesting superiority of laparoscopy to open approach, the
authors designed COST as a non-inferiority trial. Data
was accrued from 1995 through 2001. It excluded can-
cers located in the transverse colon and rectum. The pri-
mary endpoint was time from randomization to tumor
recurrence [5].
Early data was published in 2002, outlining the bene-
fits of laparoscopy in the early postoperative period.
Patients reported improved quality of life and a signifi-
cantly shorter hospital stay compared to the open group
(5 vs. 6 days, p< 0.001). The laparoscopic group also
required one less day of analgesia. These benefits have
been supported by the other RCTs [2]. The conversion
rate to open resection was 21%, and remained consistent
throughout the study course. Three-year data showed no. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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p = 0.51) or recurrence (lap: 16%, open: 19%; p = 0.32) [5].
Five-year data was available on 90% of patients and
published in 2007. COST showed that with 170 recur-
rences and 252 deaths, cancer-free and overall 5-year
survival was similar between open and laparoscopic
groups. The rate of recurrence, along with the sites of
those recurrences, was also similar (lap: 76%, open: 74%;
p = 0.93). Although not adequately powered, an explora-
tory subset analysis was done to evaluate whether con-
version to open operation impacted the outcome
measures. This analysis did not identify a significant dif-
ference between groups for either cancer-free survival or
recurrence [6].
Color: colon cancer laparoscopic or open resection
COLOR included 29 European centers with data from
1076 patients accrued from 1997 through 2003. As in
the COST trial, transverse colon and extra-peritoneal
rectal cancer were excluded. COLOR, however, also
excluded those with a body mass index greater than 30
as obesity was considered a technical challenge at the
time of this study’s design. The primary endpoint was
cancer-free survival at 3 years. Similar to the COST
study, COLOR was designed as a non-inferiority RCT.
Also like COST, COLOR included surgical teams that
had performed at least 20 laparoscopic colectomies, con-
firmed by evaluation of videotaped operations. The rate
of conversion was 17% mostly (34%) due to encounter-
ing unexpected bulky disease. The majority of patients
in this trial had only barium enema radiography and col-
onoscopy pre-operatively. Only 5% of the patients in this
trial had pre-operative computerized axial tomography
(CT) evaluation. This emphasizes the importance of pre-
operative radiographic staging with imaging tools such
as magnetic resonance imaging (MRI) and CT to facili-
tate operative planning.
Short-term results were published in 2005, describing
laparoscopy as a longer operation (lap: 145 min, open:
115 min; p< 0.0001) with less blood loss (lap: 100 cc,
open: 175 cc; p< 0.0001). There were no significant dif-
ferences in oncologic outcomes including the rate of
positive margins (p = 1.0) or in the number of lymph
nodes harvested (p = 0.35). Postoperative morbidity was
also similar for both groups with no significant differ-
ences in postoperative pulmonary or cardiac events,
anastomotic failures or wound infections [7].
At 3 years, COLOR found recurrences, whether
local, distant or combined, were similar between both
groups. Overall and cancer-free survival were not sig-
nificantly different, regardless of disease stage. The 3-
year cancer-free survival for all stages was 72.4% in
the laparoscopic group and 76.4% in the open group
(p = 0.7). Overall survival at 3 years for all stages was81.8% in the laparoscopic group and 84.2% in the open
group (p= 0.45) [8].
Although the actual difference in cancer free survival
at 3 and 5 years was small, the study did not reach its
predetermined non-inferiority margin and thus could
not rule out a difference in disease-free survival at 3 years
in favor of open colectomy. The authors selected 7% as
the cutoff to show non-inferiority regarding the differ-
ence in cancer-free survival (survival in patients having
laparoscopic operation subtracted from that of those
having open operation). At 3 years this difference was
2.0% (95% CI −3.2 to 7.2) and at 5 years was 1.4% (−4.6
to 7.5). Because the upper limit of the 95% confidence
interval is greater than 7%, non-inferiority could not be
confirmed. This difference is very small, however, and
the clinical implications are unlikely to be significant.
Additionally, if patients are analyzed by the treatment
they actually received rather than by intention to treat,
this difference does meet their criteria for non-inferiority
(1.7% 95% CI–3.5 to 6.9). Also, 3 and 5 year differences
in overall survival meet the criteria for non-inferiority
(3 years 2.4% (95% CI −2.1 to 7.0) and 5 years 0.4%
(−5.3% to 6.1), though this was not a primary endpoint
of the study.
Classic: conventional versus laparoscopic-assisted surgery
in colorectal cancer
CLASICC included 794 patients accrued from 27 United
Kingdom centers between 1996 and 2002. The CLA-
SICC study stood out among the other RCTs during this
time by including patients with rectal cancer. Patients in
this study were randomized in a 2:1 basis, such that 526
were in the laparoscopic group and 268 in the open
group. Of the 794 patients, 413 (52%) had colon cancer.
The findings for patients with rectal cancer will be dis-
cussed separately. The short-term primary endpoints
were rates of positive circumferential and longitudinal
resection margins, proportion of Dukes’ C2 tumors and
in-hospital mortality. Long-term endpoints were defined
as survival, recurrence and quality of life at 3 and 5 years,
of which results are now available.
Short-term results were reported in 2005. Overall,
there were no significant differences noted with regard
to the stated short-term endpoints and quality of life.
There was no significant difference in the number of
lymph nodes or the number of positive margins for colon
cancer, supporting that laparoscopy provided an adequate
oncologic resection. The group suggested that this
would predict a local recurrence rate no higher and a
cancer-related survival no shorter than open resection [9].
These favorable early results of CLASICC prompted a
2006 modification of the National Institute of Health and
Clinical Excellence guideline to consider laparoscopic re-
section as an option for those with colon cancer. These
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other international RCTs for colon cancer.
The CLASICC group did find more complications
among patients converted to open operation. The rate of
conversion for colon cancer was 25% and for rectal can-
cer was 34%. The most common cause for conversion in
both groups was fixation of the tumor. Of rectal cancers,
20% were converted because the tumor was deemed in-
accessible laparoscopically. This may attest to the greater
technical challenge of laparoscopy for low anterior resec-
tion (LAR) and abdominoperineal resections (APR). A
learning curve was identified with a decrease in overall
rate of conversions to 16% by year 6 from 38% noted in
year 1. Converted cases had a significantly higher rate of
intraoperative complications, including intraoperative
hemorrhage or arrhythmia (p = 0.002). Converted cases
also had a trend towards higher death rate than open or
laparoscopic arms (9% vs. 5% and 1%, respectively;
p = 0.34), though this was not statistically significant.
The main cause of death in these patients was cardiore-
spiratory failure. These effects on overall survival per-
sisted at 5 years, with lower survival for those who were
converted (p = 0.033). There was no significant difference
in distant recurrence rates for converted cases [9,10].
Recently published 5-year data supports the initial
short-term and 3-year results, strengthening the argu-
ment that laparoscopy provides short-term benefits that
do not compromise long-term outcomes. Overall sur-
vival for both laparoscopic and open resections was
similar (lap: 57.9%, open: 58.1%; p = 0.848). Regarding
colon cancer, the overall survival was again not signifi-
cantly different between treatment arms (lap: 55.7%,
open: 62.7%, p = 0.253). [10] Similarly, there was no dif-
ference in 5-year cancer-free survival for colon cancer
(lap: 57.6%, open: 64.0%, p = 0.399). In total, one wound
site recurrence was recorded in the open arm and nine
in the laparoscopic arm. There were no additional port-
site recurrences reported at 3 or 5 years [10,11].
Barcelona study
A single-center RCT included data from 219 patients
with colon cancer greater than 15 cm from the anal
verge accrued from 1993 through 1998. A single surgical
team performed all procedures. The primary endpoint
was cancer-related survival with data analyzed according
to the intention-to-treat principle. Short-term data sug-
gested that those in the laparoscopic group recovered
faster and had lower morbidity. Median follow up was
98 months. Long-term results were published in 2008. Al-
though overall survival and rate of recurrence favored the
laparoscopic group, this was not statistically significant.
An interesting finding in this study was a higher
probability of cancer-related survival in the laparoscopic
group, specifically those with locally advanced disease.These results have not been reproduced by other trials,
however. The group postulates that the surgical stress
response is less in laparoscopy and therefore may play a
role in the reported oncologic advantage. The underlin-
ing mechanism is attributed to less surgical trauma,
leading to less cytokine release and thus less tumor
stimulation. The role of vascular endothelial growth factor
in angiogenesis and tumor growth has been of particular
interest, as its levels are higher after open procedures [12].
The Barcelona study group acknowledges the laparo-
scopic advantage they identify may be attributable to it
being a single center study with outcomes dependent on
the surgeons’ experience. This suggests that the potential
for long-term benefit from laparoscopy may be found in
those who perform the procedure more frequently [13].
Although it is a single center trial, the Barcelona study
has been included in meta-analyses with the three multi-
institutional studies because of the large population
evaluated.
Rectal cancer
The application of laparoscopy for rectal cancer is
appealing. Total mesorectal excision is the standard of
care for rectal cancer and has been shown feasible lap-
aroscopically [14-16]. The advantage of a magnified view
with laparoscopy may reduce injury to the surrounding
structures, including the autonomic plexus of nerves.
Theoretically, this should reduce complications asso-
ciated with rectal cancer resection, including urinary and
sexual dysfunction.
In contrast to the available data for colon cancer, there
is limited quality data for the application of laparoscopy
for rectal cancer. There are several single-institution
reports supporting the feasibility and equivalent long-
term outcomes of laparoscopy. Nevertheless, the CLA-
SICC study provides the highest level of evidence to
date. Current on-going studies, including the American
College of Surgeons Oncology Group (ACSOG) Z6051
and the Robotic versus Laparoscopic Resection for Rectal
Cancer (ROLARR), aim to provide a rigorous evaluation
of these approaches to the treatment of rectal cancer.
Classic: rectal cancer
The CLASICC study found that the laparoscopic arm for
rectal cancer was more likely to have undergone a total
mesorectal excision. This supports the ability to maintain
standard of care using a laparoscopic approach. Short-
term results, however, found a trend towards positive cir-
cumferential resection margins in those undergoing lap-
aroscopic LAR (lap: 12%, open: 6%, (p= 0.19). This raised
concerns of increased risk for local recurrence [9].
Three and 5-year data, however, did not identify an
increased risk for local recurrence among patients hav-
ing laparoscopic operation for rectal cancer. Specifically,
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laparoscopy and 7.6% for open (p = 0.740). Five-year data
was not provided for the local recurrence rates for
patients in the APR group, but there was no significant
difference identified. Overall, the distant recurrence rate
was 20.9% found in 111 cases at 5 years. There was no
significant difference between either technique (lap: 21%,
open: 20.6%; p = 0.820) [10,11].
Overall survival was also equivalent for laparoscopic
and open resection of rectal cancer (lap: 60.3%, open:
52.9%; p = 0.132). Similar results were found regardless
of whether patients underwent LAR or APR (LAR: lap:
62.8%, open: 56.7%;p = 0.247, APR: lap: 53.2%, open:
41.8%; p = 0.310). In fact, data at three years suggested a
trend towards improved survival with laparoscopy in
Dukes’ A patients, though this did not persist at 5 years
(p = 0.491). This suggests that there is no difference in
overall survival at 5 years between treatment arms for
any stage of rectal cancer [10,11]. Cancer-free survival at
5 years was also not significantly different for patients
with rectal cancer (lap: 53.2%, open: 52.1%; p = 0.953).
The 5 year cancer-free survival was not significantly dif-
ferent for LAR (lap: 57.7%, open: 57.6%; p = 0.832) or for
APR (lap: 41.4%, open: 36.2%; p = 0.618).
Patients requiring conversion from laparoscopic to
open operation during resection for rectal cancer fare
worse with significantly decreased 5 year overall survival
(lap: 62.4%, open: 58.5%, conversion 49.6%; p = 0.005).
Based on sensitivity analysis, this worse overall survival
outcome was maintained even for surgeons with lower
than average conversion rate, suggesting surgeon-related
factors were unlikely related.
The Comparison of Open versus laparoscopic surgery
for mid and low Rectal cancer After Neoadjuvant che-
moradiotherapy (COREAN) trial is another randomized
trial recently published showing equivalent short-term
oncologic outcomes between open and laparoscopic sur-
gery for rectal cancer. The trial included 340 patients
with cT3N0-2 mid or low rectal cancer without distant
metastasis. Conversion to an open procedure occurred
in 2 patients (1.2%). Along with equivalence of oncologic
outcomes, other short-term outcomes such as recovery
of gastrointestinal function, analgesia requirement, and
return to physical function showed improvement in the
laparoscopic group [17].
COLOR II is an ongoing non-inferiority RCT that has
27 participating international sites with 739 patients, fo-
cusing on the outcomes from laparoscopic versus open
rectal cancer resection. [18,19] Several individual studies
have shown that laparoscopic total mesorectal excision
is feasible and safe but CLASSICC is the only RCT to
reliably support laparoscopic resection as an adequate
and equivalent treatment for rectal cancer. Inclusion cri-
teria for COLOR II include a single rectal mass within15 cm of the anal verge on rigid proctoscopy or distal to
the conjugate line on CT/MRI. Preoperative imaging is
required to exclude distant metastasis. Tumors amen-
able to local excision and those with radiographic fea-
tures suggestive of local invasion are excluded. The
primary endpoint for this study will be loco-regional re-
currence at 3 years.
Three other smaller, single-center RCT studies were
included along with the CLASICC study in the
Cochrane meta-analysis of operative approaches to rectal
cancer. Those smaller trials will be discussed here. The
first by Araujo et al. included 28 patients and focused on
laparoscopic versus open APR after neoadjuvant therapy.
No conversions were performed. Mean follow up was
47 months and only postoperative complications and
local recurrence were noted. They found significantly
fewer lymph nodes harvested in the laparoscopic group
(5.5 nodes) compared to open (11.9) (p = 0.04). They
attributed this difference to the small number of
patients. At 47 months of follow up, two local recur-
rences were noted in the open group and none in the
laparoscopic group [20].
The second trial included in the Cochrane analysis by
Zhou et al. included 171 patients, comparing open and
laparoscopic low and ultralow anterior resection.
Included patients had the distal margin of tumor distal
to the peritoneal reflection and 1.5 cm above the dentate
line. Total mesenteric excision with anal sphincter pres-
ervation was accomplished in all patients. The average
operative time was not significantly different (lap:
120 min, open: 106 min; p> 0.05) although blood loss
was significantly less with laparoscopy (lap: 20 mL, open:
92 mL; p< 0.05). The outcomes of this study included
postoperative recovery and local recurrence. There was
no significant difference in days until start of fluid intake
(p = 0.713) or in days of analgesia (p = 0.225). Days to
first bowel movement was significantly shorter in the
laparoscopic group (lap: 1.5 days, open: 2.7 days;
p = 0.009). The number of hospital days was also signifi-
cantly shorter in the laparoscopy group (lap: 8.1 days,
open: 13.3 days; p = 0.001). Postoperative complications
such as urinary retention, infection, obstruction and
anastomotic leakage were significantly decreased with
laparoscopy (lap: 6.1%, open: 12.4%; p = 0.016). Two port
site recurrences were noted in the laparoscopic group
and 3 pelvic local recurrences in the open group. Statis-
tical significance was not reported. No mortalities were
noted in the 1 to 16 month follow-up. The authors con-
clude that adequate resection of low rectal cancers can
be performed laparoscopically but is a technically chal-
lenging approach. Long-term results regarding survival
were not reported in this study [21].
The third study in the Cochrane analysis by Braga
et al. followed the 5-year outcomes in 391 patients with
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cancer with 68 in the laparoscopic group and 68 in the
open group. The outcomes in this study were not classi-
fied between colon and rectal cancer patients. No differ-
ence was found with respect to number of lymph nodes
recovered. Distal and radial margins were negative in all
patients. The rate of conversion was 4.2%. Outcomes
measured included postoperative morbidity and disease-
free survival. The rate of anastomotic leak was not sig-
nificantly different (lap: 4.7%, open: 6.9%; p = 0.46). Reo-
peration was required in 6.3% of laparoscopic cases due
to anastomotic leak in seven, adhesive disease in three,
and bleeding in two cases compared to 9.4% of open
cases, with anastomotic leak in 11, adhesive disease in
six, and bleeding in two cases (p = 0.34). The length of
stay was significantly shorter for the laparoscopic group
(lap: 9.4 days, open: 12.7 days; p = 0.0001). Long-term
complications were also noted to be significantly lower
in the laparoscopic group overall (lap: 6.8%, open: 14.9%;
p = 0.02). Follow-up was between 15 to 60 months. Five-
year overall and disease-free survival were not signifi-
cantly different between open or laparoscopic groups al-
though p-values were not provided. Of note, the study
describes that the local recurrence rate in rectal cancer
was 7.3% in the laparoscopic group and 8.8% in the open
group, with no p-value provided [22].
The ACSOG Z6051 study published data of their phase
II pilot study in 2011 supporting that laparoscopic-assisted
resection had both acceptable oncologic and perioperative
clinical outcomes when compared to open resection. The
pilot study was created with the intention to provide base-
line parameters for a planned randomized control trial.
This included the data of 54 patients with stage I to III rec-
tal cancer obtained from 2001 to 2005. Exclusion criteria
included stage IV cancer, pregnancy, and patients with ASA
IV and V. Three surgeons performed the laparoscopic pro-
cedures, all with extensive laparoscopic experience (>300
procedures for colorectal disease and >20 laparoscopic rec-
tal dissections). Pouch reconstruction and hand-assisted
approaches were based on surgeon preference. Follow-up
data was collected up to 5 years post-operatively.
Perioperative results described significantly earlier re-
turn of bowel function in the laparoscopic group
(p = 0.03). There was no significant difference in the
complication rate (lap: 22.2%, open: 32.4%; p = 0.178).
Local recurrence was similar (lap: 2%, open: 4.2%,
p = 0.417) as was 5-year overall survival (lap: 90.8%,
open: 88.5%; p = 0.261) and disease-free survival (lap:
80.8%, open: 75.8%; p = 0.390). All cases of local recur-
rence occurred within 2 years. Conversion to open resec-
tion occurred in 6 cases (11.1%) and reasons included
difficulty obtaining sufficient length and difficulty in com-
pleting the anastomosis. A positive circumferential rectal
margin was found in one laparoscopic case, compared to7 in the open group (p> 0.05). This was noted to be the
opposite of CLASICC findings. Nevertheless the 3-year
local recurrence and survival were not different between
either laparoscopic or open approaches, which is also seen
in the ASCOG Z6051 study.
Authors of the Z6051 pilot trial identify the study size
as a major limitation, despite well-matched groups.
Nevertheless, the current data suggests that the laparo-
scopic approach provides the potential for acceptable
outcomes [23]. The Phase III randomized controlled trial
arm of the study is currently recruiting patients.
As the aforementioned studies provide encouraging
data supporting the efficacy of laparoscopic approaches
to rectal cancer, other centers seek to evaluate the out-
comes of robotic-assisted laparoscopy in this setting.
Given the technical difficulties of applying laparoscopy
to the confined pelvic space, robotic assistance has the
advantage of providing manipulation of instruments with
7-degrees of freedom of movement, as well as enhance-
ment of dexterity and field of view. To date, there are a
number of case series as well as one published rando-
mized trial with 18 patients showing no difference in the
outcomes, conversion rates or operative time comparing
robotic-assistance to standard laparoscopy [24].
The Robotic versus Laproscopic Resection for Rectal
Cancer (ROLARR) trial is a prospective, randomized,
controlled, multi-center, unblinded superiority which
began recruiting in 2010 seeking to primarily investigate
rate of conversion, circumferential margin positivity, 3-year
local recurrence and overall outcomes of the robotic-
assisted approach. Other outcomes of interest include cost-
effectiveness and quality of life The authors aim for about
400 patients to maintain 80% power. Participating surgeons
are required to have performed at least 10 robotic-assisted
resections. Along with measuring overall oncologic out-
comes, ROLARR seeks to evaluate the clinical benefits of
robotics, including preservation of normal bladder and sex-
ual function. Given the costs of robotic systems, these mea-
sures are essential to justify the use of robotics [25].
In conclusion, the larger CLASICC study and the three
smaller single-center studies support that the laparo-
scopic approach to rectal cancer appears to provide an
adequate oncologic excision with similar long-term out-
comes. Current studies such as the Z6051, ROLARR and
COLOR II studies can provide further insight on the
outcomes of these minimally invasive approaches.
Meta-analyses
Among the available research evaluating operative ap-
proach to colorectal cancer, the aforementioned studies
are referred to most frequently for their prospective,
multi-institutional design and large patient number.
Nevertheless, each study has inherent weaknesses
acknowledged by their authors. For this reason, several
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power of the argument that laparoscopy is a safe and
oncologically sound approach to the operative treatment
of colorectal cancer.
The 2007 meta-analysis by Bonjer, et al. includes the
four studies described above, chosen for their accrual of
more than 150 patients each with data available up to
3 years post-randomization at the time of meta-analysis.
Ultimately, data from 1536 patients was analyzed for
outcomes in colon cancer alone. Overall results reflected
the favorable outcomes from the individual studies.
There was no significant difference among the studies
with regard to patient age, cancer stage distribution,
mean number of lymph nodes recovered (p = 0.40), rate
of positive margin (p = 0.23), or postoperative mortality
(p = 0.63). Three-year cancer free survival was not sig-
nificantly different (p = 0.83) nor was the overall survival
(p = 0.56) between laparoscopic and open resections.
Tumor recurrence was noted in 121 open and 113 laparo-
scopic resections. The percentage of local, distant and
combined local and distant recurrences was not signifi-
cantly different between groups (p= 0.43, χ2 test). When
analyzed for differences of overall survival by cancer stage,
there was no significant difference identified [26].
Other meta-analyses included smaller studies in
addition to the four studies analyzed by Bonjer. Despite
the heterogeneity of reported results in those studies,
the meta-analyses agree that there is no significant dif-
ference in survival, recurrence or lymph node recovery
for open or laparoscopic resection. Jackson et al. in 2007
included both colon and rectal cases in their analysis of
10 RCTs, with the same conclusions [27].
A 2008 Cochrane Review was performed for both
colon and rectal cancers, analyzing 12 trials involving
3346 patients. In colon cancer, there was no significant
difference in local recurrence between treatment arms
(4 RCTs with 938 patients, p = 0.57), in wound recurrence
(p= 0.16) or in cancer-related mortality (5 RCTs with
1575 patients, p = 0.15). In rectal cancer, there was no sig-
nificant difference in local recurrence (4 RCTs with 714
patients, p = 0.46) or cancer-related mortality (3 RCTs
with 578 patients, p = 0.16) [28].
The currently available meta-analyses are reassuring
for continuing laparoscopic resection for colon cancer.
A meta-analysis including the current 5-year data from
the larger trials would further strengthen this argument.
Two of the meta-analyses also suggest that laparoscopic
resection of rectal cancer may be safe and oncologically
adequate, although long-term data and results of large
randomized trials are forthcoming.
Single-incision laparoscopic resection
As 5-year data supports laparoscopic resection of colon
cancer with no significant increased risk of wound siterecurrence, surgeons are already considering the next
step in further minimizing the invasiveness of the tech-
nique. The use of SIL for colonic resection has been
reported in case series, supporting its feasibility and
safety [29]. Some reports include both benign and malig-
nant disease but the small number of patients, as well as
the inadequate reporting of adequate oncologic resec-
tion, limits subgroup analysis. In addition, the SIL tech-
nique adds an additional layer of technical complexity
that limits widespread application at this time.
Papaconstantinou and Thomas reported a case-
matched comparison in 2011 of SIL versus multiport
laparoscopic colectomy for colon cancer with 1-year out-
comes. The study included 26 SIL colectomy patients
from 2009 to 2010 matched for factors including age,
body mass index, and American Society of Anesthesiolo-
gists score. [30] Mean operative time was not signifi-
cantly different at 144 minutes (p = 0.98). Total
conversion rates were similar as well. The SIL group had
a 12% conversion rate (2 to multiport and 1 to a hand-
assisted port) and the multiport group had 15% conver-
sion rate (3 to hand-assisted port and 1 to open). There
was no difference noted regarding the number of lymph
nodes harvested (SIL:18, multiport: 17; p = 0.88) or in-
volvement of proximal, distal or radial margins
(p= 0.21). The length of stay was noted to be shorter by
1.4 days in the SIL group, which was significant (p< 0.05).
The mean follow-up was significantly shorter for the SIL
group at 13 months compared to multiport at 21 months
(p< 0.001) since all the multiport cases predated the SIL
cases. At one year, there were no deaths or port-site recur-
rences noted. Each group was found to have 8% recur-
rence, all of which were distant metastasis in patients with
stage III disease. One-year survival was similar at 92% for
SIL and 92% for multiport (p = 0.97).
This work provides promising early evidence that the
SIL may be an additional option for colon cancer resec-
tion to further reduce morbidity. The authors do not
suggest SIL for rectal cancer at this time.
Conclusions
Several large RCTs support that laparoscopic resection is
not inferior to open resection of colorectal cancer. This
is likely due to technical principles that are maintained
during both open and laparoscopic operations, including
the ligation of the primary feeding vessel at its base,
minimal and atraumatic handling of the tumor, total
mesorectal excision and accrual of at least 12 lymph
nodes with adequate margins. Patients undergoing lap-
aroscopic resection are in the operating room longer but
are in the hospital for a shorter time. Most importantly,
these key studies continue to support that an adequate
oncologic resection can be performed laparoscopically
without compromising outcomes.
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safety and adequacy of laparoscopic resection in colon
and rectal cancer. Future data from these trials will be
helpful to reinforce confidence in this technique. Add-
itional outcomes from current RCTs such as one from
Australia for colon cancer and the aforementioned
COLOR II trial for rectal cancer are highly anticipated.
[31]. While the use of SIL as is appealing, its application
and outcomes must also be evaluated as rigorously as
that of laparoscopic resections for colon and rectal can-
cer before widespread use can be encouraged.
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